Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT02022540 Completed - Clinical trials for Age-Related Macular Degeneration (AMD)

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Start date: February 2014
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).

NCT ID: NCT02022501 Completed - Clinical trials for Age-Related Macular Degeneration

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Start date: January 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, bioactivity and pharmacokinetics of three concentrations of DE-120 after a single intravitreal injection in subjects with late stage exudative age-related macular degeneration.

NCT ID: NCT02016508 Recruiting - Clinical trials for Age Related Macular Degeneration

Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration

Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral intravitreally transplantation of adult bone marrow stem cells in subjects with geographic atrophy secondary to age-related macular degeneration.

NCT ID: NCT02005133 Terminated - Clinical trials for Wet Age-related Macular Degeneration

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Start date: November 2013
Phase: N/A
Study type: Observational

To assess the use of aflibercept over a 2 year period in VEGF inhibitor naive and prior treated wet AMD patients managed in 'real wold' clinic settings.

NCT ID: NCT02002377 Terminated - Clinical trials for Age Related Macular Degeneration

Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

SHIFT-2
Start date: April 17, 2014
Phase: Phase 4
Study type: Interventional

SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.

NCT ID: NCT01997164 Completed - Clinical trials for Diabetic Macular Edema

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Start date: November 2014
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with diabetic macular edema (DME).

NCT ID: NCT01996215 Completed - Clinical trials for Age-Related Macular Degeneration

Brain Connectivity in Age-Related Macular Degeneration

Start date: April 2014
Phase:
Study type: Observational

This study is to determine how cognitive deficits (e.g.,verbal fluency deficit) in patients with Age-Related Macular Degeneration (AMD) relate to specific aspects of brain and function. The study team will assess whether the "brain signatures" associated with specific cognitive deficits differ in older adults with and without AMD.

NCT ID: NCT01991730 Recruiting - Clinical trials for Age Related Macular Degeneration

Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients

Start date: October 2013
Phase: N/A
Study type: Observational

This open-label, Phase IV prospective, observational study will evaluate patients, who have been diagnosed with Neovascular Age-Related Macular Degeneration and have previously received either a standard intravitreal injection of ranibizumab or aflibercept, in order to get and compare information regarding post-injection inflammatory (irritation in the eye)2-3 days post-injection. Additionally, patients will be evaluated for visual acuity and pain 2-3 days post-injection. THIS IS AN OBSERVATION STUDY AND NOT AN INTERVENTIONAL STUDY AS TO ENTER THIS STUDY SUBJECTS WILL HAVE HAD TO RECEIVED EITHER RANIBIZUMAB 0.5 MG OR AFIBERCEPT 2MG PRIOR TO ENTERING THE STUDY AND SIGNING CONSENT. THIS STUDY IS TO OBSERVE THE SUBJECT POST-INJECTION RECEIVED BEFORE ENTERING THIS STUDY.

NCT ID: NCT01988662 Completed - Clinical trials for Neovacular Age-related Macular Degeneration

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD

UNRAVEL
Start date: April 2014
Phase: Phase 4
Study type: Interventional

This study will assess systemic VEGF level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept

NCT ID: NCT01986907 Completed - Clinical trials for Wet Age Related Macular Degeneration

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

TWEYES
Start date: March 4, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).